background:alpha-synuclein is a member of synuclein family of proteins with unidentified function localized in the cytoplasm, mitochondria of neurons, and presynaptic nerve endings. although it is found in the lewy bodies in synucleinopathies and in alzheimer’s disease, the protein could also be considered as a novel marker in diagnosis of diseases related to the hematopoietic system. methods: ...

acute myeloid leukemia (aml) is a type of poor prognosis hematological malignancies characterized by heterogeneous clonal expansion of myeloid progenitors. leukemic stem cells are thought to form the majority of a cell population in minimal residual diseases (mrds) which are resistant to current chemotherapeutic regimens and mediate disease relapse. current therapeutic vaccine strategies have d...

Patients with acute myeloblastic leukemia (AML) with monosomy 7 are a group of patients with refractory AML who have a very poor prognosis. Therefore, rationally designed new therapies, including metronomic chemotherapy regimen with histidine deacetylase inhibitors (Valporic acid, ATRA) are being investigated as potential treatments for the population of refractory cases of AML. Herein, we repo...

Objectives: A novel flow cytometric ‘AML Maturity Score (AMS)’ classifying patients into AML-immature (AML-im) and AML-mature (AML-ma) based on CD34, CD117 Tdt expression blasts correlated with induction remission, relapse free survival overall in previous studies. We aimed to study the correlation between AMS ELN risk group outcomes- remission (IR), time (TTR) relapse.
 Material Methods: ...

Background: Acute myeloid leukemia (AML) is a malignant disorder involving blood cells, characterized by obstructed or distorted differentiation of hematopoietic stem cells. In cytogenetically normal AML (CN AML), molecular abnormalities in NPM, FLT3, CEBPA, and BAALC genes are observed. Initially, high BAALC (Brain and Acute Leukemia Cytoplasmic gene) expression was introduced in a study on AM...

introduction: arsenic has been used as an effective medicine in the treatment of severe promyelocytic leukemia in recurrence and resistance cases toward atra. in this study, it has been used as induction and maintenance therapy after remission. method & material: we studied 31 patients diagnosed by apl. a rsenic was started at a dose of 0.15 mg/kg (daily) until patient’s bone marrow remission.(...

In acute myeloid leukaemia (AML) t(8;16)(p11;p13)/MYST3–CREBBP is a very rare abnormality. Previous small series suggested poor outcome. We report on 59 patients with t(8;16) within an international, collaborative study. Median age was 52 (range: 16–75) years. AML de novo in 58%, therapy-related (t-AML) 37% and secondary after myelodysplastic syndrome (s-AML) 5%. Cytogenetics revealed complex k...